EMA evaluating the use of COVID-19 Vaccine Moderna in young people aged 12 to 17

The CHMP will carry out an accelerated assessment of data submitted in the application, including results from a large ongoing clinical study. The outcome, together with any requirements for further studies and additional safety monitoring, is expected in July.

Source:

European Medicines Agency